JP5514736B2 - ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物 - Google Patents

ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物 Download PDF

Info

Publication number
JP5514736B2
JP5514736B2 JP2010542410A JP2010542410A JP5514736B2 JP 5514736 B2 JP5514736 B2 JP 5514736B2 JP 2010542410 A JP2010542410 A JP 2010542410A JP 2010542410 A JP2010542410 A JP 2010542410A JP 5514736 B2 JP5514736 B2 JP 5514736B2
Authority
JP
Japan
Prior art keywords
group
substituted
unsubstituted
polyoxazoline
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010542410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011510120A (ja
JP2011510120A5 (https=
Inventor
ハリス,ジエイ・ミルトン
ベントレー,マイケル・デイビツド
ユン,クンサン
Original Assignee
セリナ・セラピユーテイツクス・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セリナ・セラピユーテイツクス・インコーポレーテツド filed Critical セリナ・セラピユーテイツクス・インコーポレーテツド
Publication of JP2011510120A publication Critical patent/JP2011510120A/ja
Publication of JP2011510120A5 publication Critical patent/JP2011510120A5/ja
Application granted granted Critical
Publication of JP5514736B2 publication Critical patent/JP5514736B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/06Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/0233Polyamines derived from (poly)oxazolines, (poly)oxazines or having pendant acyl groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/028Polyamidoamines
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
JP2010542410A 2008-01-11 2009-01-12 ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物 Active JP5514736B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2068408P 2008-01-11 2008-01-11
US61/020,684 2008-01-11
US2933708P 2008-02-16 2008-02-16
US61/029,337 2008-02-16
PCT/US2009/030762 WO2009089542A2 (en) 2008-01-11 2009-01-12 Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

Publications (3)

Publication Number Publication Date
JP2011510120A JP2011510120A (ja) 2011-03-31
JP2011510120A5 JP2011510120A5 (https=) 2013-06-27
JP5514736B2 true JP5514736B2 (ja) 2014-06-04

Family

ID=40853790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010542410A Active JP5514736B2 (ja) 2008-01-11 2009-01-12 ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物

Country Status (7)

Country Link
US (2) US8110651B2 (https=)
EP (3) EP3042922B1 (https=)
JP (1) JP5514736B2 (https=)
KR (1) KR101486449B1 (https=)
CN (1) CN101959934B (https=)
DK (1) DK3042922T3 (https=)
WO (1) WO2009089542A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5514736B2 (ja) 2008-01-11 2014-06-04 セリナ・セラピユーテイツクス・インコーポレーテツド ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
US8883211B2 (en) * 2008-07-10 2014-11-11 Serina Therapeutics, Inc. Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds
CN103429268B (zh) * 2011-01-04 2015-11-25 本德尔分析控股有限公司 从亲电活化的聚噁唑啉衍生的经交联的聚合物和植入物
CN102731791B (zh) * 2011-04-13 2016-04-13 北京大学 温度敏感型嵌段共聚物及其水凝胶和其用途
US8383093B1 (en) * 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
US20140271527A1 (en) * 2011-11-01 2014-09-18 Serina Therapeutics, Inc. Subcutaneous delivery of polymer conjugates of therapeutic agents
CN104024306B (zh) * 2012-01-02 2017-06-13 根特大学 聚噁唑啉聚合物及其制备方法、这些聚合物的结合物及其医疗用途
JP6178399B2 (ja) 2012-03-16 2017-08-09 ベンデル アナリティカル ホールディング ビー.ブイ.Bender Analytical Holding B.V. 求核的に活性化したポリオキサゾリンに由来する架橋ポリマー及び医療製品
MX366404B (es) 2012-11-15 2019-07-08 Apellis Pharmaceuticals Inc Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados.
CN106715533B (zh) * 2014-07-31 2020-03-13 塞瑞纳治疗公司 聚恶唑啉抗体药物结合物
AU2015321646B2 (en) 2014-09-26 2017-11-30 Alcon Inc. Polymerizable polysiloxanes with hydrophilic substituents
CA2963057C (en) 2014-10-06 2023-08-01 Gatt Technologies B.V. Tissue-adhesive porous haemostatic product
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
CN105418911A (zh) * 2015-12-29 2016-03-23 南京工业大学 一种聚(2-r-2-噁唑啉)嵌段聚(肌氨酸)双亲性嵌段共聚物的制备方法
IL269844B2 (en) 2017-04-07 2025-01-01 Apellis Pharmaceuticals Inc Dosage regimens and related compositions and methods
DE102018000650A1 (de) * 2018-01-27 2019-08-01 Friedrich-Schiller-Universität Jena Verfahren zur Bestimmung von Verunreinigungen in Polyalkylenethern oder Polyalkylenaminen und dessen Verwendung
EP3829577A4 (en) * 2018-07-27 2022-12-21 Serina Therapeutics, Inc. CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT THEREOF
US12485181B2 (en) 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
CN113354811B (zh) * 2020-02-19 2024-05-07 华东理工大学 一种侧链含有氨基和/或羟基的噁唑啉聚合物,其制备方法及应用
CN112661961B (zh) * 2020-12-28 2022-05-06 中国科学院长春应用化学研究所 两亲性聚噁唑啉共聚物、其制备方法及应用
US12233132B2 (en) 2021-02-09 2025-02-25 Serina Therapeutics, Inc. Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
KR20230044782A (ko) 2021-09-27 2023-04-04 삼성전자주식회사 패치 안테나를 포함하는 안테나 구조 및 이를 포함하는 전자 장치
EP4422698A1 (en) 2021-10-29 2024-09-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2024184500A1 (en) 2023-03-08 2024-09-12 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709039A (en) * 1986-03-21 1987-11-24 The Dow Chemical Company Vinyloxazoline monomer and preparation thereof
JPH075686B2 (ja) 1988-08-22 1995-01-25 フューズド・コンタクツ・オブ・シカゴ・インコーポレイテッド 改善された気体透過コンタクトレンズを作るための組成
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5130126A (en) 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5635571A (en) * 1995-06-30 1997-06-03 Cornell Research Foundation, Inc. Polymerizable macromonomers and polymers prepared therefrom
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
DE19936014C2 (de) 1999-08-04 2003-04-03 Zf Lemfoerder Metallwaren Ag Gummilager mit axialer Dämpfung
WO2001076639A2 (en) 2000-04-06 2001-10-18 Pharmacia Corporation Chemically-modified myelopoietin conjugates
KR20030057529A (ko) 2000-09-08 2003-07-04 그리폰 테라퓨틱스, 인코포레이티드 합성 적혈구생성 자극 단백질
WO2002032957A1 (en) 2000-10-16 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
US6759496B2 (en) * 2000-12-18 2004-07-06 Bausch & Lomb Incorporated Poly(2-oxazoline) biomedical devices
AU2002233230B2 (en) 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
US7077939B1 (en) 2001-06-18 2006-07-18 The Texas A&M University System Method and apparatus for nanoparticle transport and detection
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
JP3984541B2 (ja) * 2001-12-26 2007-10-03 財団法人川村理化学研究所 星型ポリオキサゾリンからなる粒子およびその製造方法
WO2003066069A1 (en) 2002-02-01 2003-08-14 Intradigm Corporation Polymers for delivering peptides and small molecules in vivo
EP1344810A1 (en) 2002-03-13 2003-09-17 Infineum International Limited Fuel additive compositions for diesel engine equipped with a particulate trap
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
CA2527665A1 (en) 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
PT1512736T (pt) 2003-09-05 2018-05-29 Infineum Int Ltd Composições estabilizadas de aditivos para gasóleo
US8057821B2 (en) * 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
EP2134181A4 (en) 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
JP5514736B2 (ja) * 2008-01-11 2014-06-04 セリナ・セラピユーテイツクス・インコーポレーテツド ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

Also Published As

Publication number Publication date
KR20110007084A (ko) 2011-01-21
JP2011510120A (ja) 2011-03-31
EP3042922B1 (en) 2017-07-19
WO2009089542A3 (en) 2009-10-01
US9169354B2 (en) 2015-10-27
EP2235090A4 (en) 2011-10-05
EP2669313B1 (en) 2016-03-23
US20110009594A1 (en) 2011-01-13
WO2009089542A2 (en) 2009-07-16
US8110651B2 (en) 2012-02-07
EP2235090B1 (en) 2013-09-04
EP3042922A1 (en) 2016-07-13
EP2669313A1 (en) 2013-12-04
US20120136123A1 (en) 2012-05-31
CN101959934B (zh) 2012-12-12
CN101959934A (zh) 2011-01-26
KR101486449B1 (ko) 2015-01-26
DK3042922T3 (en) 2017-10-23
EP2235090A2 (en) 2010-10-06

Similar Documents

Publication Publication Date Title
JP5514736B2 (ja) ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
US8088884B2 (en) Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
JP5615558B2 (ja) 活性ポリオキサゾリンおよびそれを含む組成物
US11925689B2 (en) Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5642673B2 (ja) 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130507

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140331

R150 Certificate of patent or registration of utility model

Ref document number: 5514736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250